{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T00:49:03Z","timestamp":1794617343681,"version":"4.9.1"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Many factors, including reproductive hormones, have been linked to a woman\u2019s risk of developing breast cancer (BC). We reviewed the literature regarding the relationship between ovulatory menstrual cycles (MCs) and BC risk. Physiological variations in the frequency of MCs and interference with MCs through genetic variations, pathological conditions and or pharmaceutical interventions revealed a strong link between BC risk and the lifetime number of MCs. A substantial reduction in BC risk is observed in situations without MCs. In genetic or transgender situations with normal female breasts and estrogens, but no progesterone (P4), the incidence of BC is very low, suggesting an essential role of P4. During the MC, P4 has a strong proliferative effect on normal breast epithelium, whereas estradiol (E2) has only a minimal effect. The origin of BC has been strongly linked to proliferation associated DNA replication errors, and the repeated stimulation of the breast epithelium by P4 with each MC is likely to impact the epithelial mutational burden. Long-lived cells, such as stem cells, present in the breast epithelium, can carry mutations forward for an extended period of time, and studies show that breast tumors tend to take decades to develop before detection. We therefore postulate that P4 is an important factor in a woman\u2019s lifetime risk of developing BC, and that breast tumors arising during hormonal contraception or after menopause, with or without menopausal hormone therapy, are the consequence of the outgrowth of pre-existing neoplastic lesions, eventually stimulated by estrogens and some progestins.<\/jats:p>","DOI":"10.1186\/s13058-023-01661-0","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T09:04:34Z","timestamp":1685437474000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Progesterone from ovulatory menstrual cycles is an important cause of breast cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Herjan J. T.","family":"Coelingh Bennink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman J.","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. Craig","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Briggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan F. M.","family":"Egberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Gemzell-Danielsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig","family":"Kiesel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Kluivers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Krijgh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Simoncini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank Z.","family":"Stanczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"key":"1661_CR1","unstructured":"NBCC Breast Cancer Facts & Figures. https:\/\/www.stopbreastcancer.org\/information-center\/facts-figures\/ (accessed on April 11, 2022)."},{"key":"1661_CR2","unstructured":"Cancer Research UK. Breast cancer statistics. https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/breast-cancer (accessed April 11, 2022)."},{"key":"1661_CR3","unstructured":"ACS. Key statistics for breast cancer in men. https:\/\/www.cancer.org\/cancer\/breast-cancer-in-men\/about\/key-statistics.html (accessed on April 11, 2022)."},{"issue":"1","key":"1661_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.molonc.2010.11.003","volume":"5","author":"A Prat","year":"2011","unstructured":"Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol. 2011;5(1):5\u201323.","journal-title":"Mol Oncol"},{"issue":"9","key":"1661_CR5","doi-asserted-by":"publisher","first-page":"329","DOI":"10.5306\/wjco.v2.i9.329","volume":"2","author":"JD Davis","year":"2011","unstructured":"Davis JD, Lin SY. DNA damage and breast cancer. World J Clin Oncol. 2011;2(9):329\u201338.","journal-title":"World J Clin Oncol"},{"issue":"6331","key":"1661_CR6","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1126\/science.aaf9011","volume":"355","author":"C Tomasetti","year":"2017","unstructured":"Tomasetti C, Li L, Vogelstein B. Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. Science. 2017;355(6331):1330\u20134.","journal-title":"Science"},{"key":"1661_CR7","unstructured":"World Cancer Research Fund\/American Institute for Cancer Research. Diet, Nutrition, Physical Activity and Cancer: a Global Perspective. Continuous Update Project Expert Report 2018. https:\/\/www.wcrf.org\/wp-content\/uploads\/2021\/02\/Summary-of-Third-Expert-Report-2018.pdf (accessed on April 25, 2022)."},{"issue":"1","key":"1661_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-014-3211-4","volume":"149","author":"M Dowsett","year":"2015","unstructured":"Dowsett M, Folkerd E. Reduced progesterone levels explain the reduced risk of breast cancer in obese premenopausal women: a new hypothesis. Breast Cancer Res Treat. 2015;149(1):1\u20134.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"1661_CR9","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1002\/1097-0142(19850901)56:5<1206::AID-CNCR2820560541>3.0.CO;2-9","volume":"56","author":"BE Henderson","year":"1985","unstructured":"Henderson BE, Ross RK, Judd HL, Krailo MD, Pike MC. Do regular ovulatory cycles increase breast cancer risk? Cancer. 1985;56(5):1206\u20138.","journal-title":"Cancer"},{"issue":"5","key":"1661_CR10","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/00001648-199609000-00018","volume":"7","author":"H Michels-Blanck","year":"1996","unstructured":"Michels-Blanck H, Byers T, Mokdad AH, Will JC, Calle EE. Menstrual patterns and breast cancer mortality in a large U.S. cohort. Epidemiology. 1996;7(5):543\u20136.","journal-title":"Epidemiology"},{"issue":"9","key":"1661_CR11","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1023\/A:1020684821837","volume":"13","author":"F Clavel-Chapelon","year":"2002","unstructured":"Clavel-Chapelon F. Cumulative number of menstrual cycles and breast cancer risk: results from the E3N cohort study of French women. Cancer Causes Control. 2002;13(9):831\u20138.","journal-title":"Cancer Causes Control"},{"issue":"11","key":"1661_CR12","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S1470-2045(12)70425-4","volume":"13","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"2012","unstructured":"Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118,964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 2012;13(11):1141\u201351.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1661_CR13","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.contraception.2016.06.022","volume":"96","author":"HJT Coelingh Bennink","year":"2017","unstructured":"Coelingh Bennink HJT, Zimmerman Y, Laan E, Termeer HMM, Appels N, Albert A, et al. Maintaining physiological testosterone levels by adding dehydroepiandrosterone to combined oral contraceptives: I. Endocrine effects. Contraception. 2017;96(5):322\u20139.","journal-title":"Contraception"},{"issue":"1","key":"1661_CR14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.steroids.2012.10.010","volume":"78","author":"HN Bui","year":"2013","unstructured":"Bui HN, Sluss PM, Blincko S, Knol DL, Blankenstein MA, Heijboer AC. Dynamics of serum testosterone during the menstrual cycle evaluated by daily measurements with an ID-LC-MS\/MS method and a 2nd generation automated immunoassay. Steroids. 2013;78(1):96\u2013101.","journal-title":"Steroids"},{"issue":"2","key":"1661_CR15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/13625187.2017.1286313","volume":"22","author":"FJME Roumen","year":"2017","unstructured":"Roumen FJME, Zimmerman Y, Van Wijck ATK, Onghena PCBHJT. Mood disturbances during combined oral contraceptive use and the effect of androgen supplementation. Results of a double-blind, placebo-controlled, single-case alternation design pilot study. Eur J Contracept Reprod Health Care. 2017;22(2):147\u201351.","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"1","key":"1661_CR16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.contraception.2018.02.014","volume":"98","author":"RHW van Lunsen","year":"2018","unstructured":"van Lunsen RHW, Zimmerman Y, Coelingh Bennink HJT, Termeer HMM, Appels N, Fauser B, et al. Maintaining physiologic testosterone levels during combined oral contraceptives by adding dehydroepiandrosterone: II. Effects on sexual function. A phase II randomized, double-blind, placebo-controlled study. Contraception. 2018;98(1):56\u201362.","journal-title":"Contraception"},{"issue":"9084","key":"1661_CR17","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S0140-6736(97)08233-0","volume":"350","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"1997","unstructured":"Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997;350(9084):1047\u201359.","journal-title":"Lancet"},{"issue":"1","key":"1661_CR18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.7326\/M18-1323","volume":"170","author":"HB Nichols","year":"2019","unstructured":"Nichols HB, Schoemaker MJ, Cai J, Xu J, Wright LB, Brook MN, et al. Breast cancer risk after recent childbirth: a pooled analysis of 15 prospective studies. Ann Intern Med. 2019;170(1):22\u201330.","journal-title":"Ann Intern Med"},{"issue":"9328","key":"1661_CR19","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0140-6736(02)09454-0","volume":"360","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"2002","unstructured":"Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet. 2002;360(9328):187\u201395.","journal-title":"Lancet"},{"issue":"5","key":"1661_CR20","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1158\/0008-5472.CAN-14-2717","volume":"75","author":"F Meier-Abt","year":"2015","unstructured":"Meier-Abt F, Bentires-Alj M, Rochlitz C. Breast cancer prevention: lessons to be learned from mechanisms of early pregnancy-mediated breast cancer protection. Cancer Res. 2015;75(5):803\u20137.","journal-title":"Cancer Res"},{"issue":"9414","key":"1661_CR21","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/S0140-6736(04)15835-2","volume":"363","author":"V Beral","year":"2004","unstructured":"Beral V, Bull D, Doll R, Peto R, Reeves G, Collaborative Group on Hormonal Factors in Breast C. Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83000 women with breast cancer from 16 countries. Lancet. 2004;363(9414):1007\u201316.","journal-title":"Lancet"},{"key":"1661_CR22","volume-title":"The clinical gynaecologic endocrinology and infertility","author":"L Speroff","year":"2005","unstructured":"Speroff L, Fritz M. The clinical gynaecologic endocrinology and infertility. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2005.","edition":"7"},{"issue":"3","key":"1661_CR23","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10549-016-3691-5","volume":"155","author":"DC Radisky","year":"2016","unstructured":"Radisky DC, Visscher DW, Frank RD, Vierkant RA, Winham S, Stallings-Mann M, et al. Natural history of age-related lobular involution and impact on breast cancer risk. Breast Cancer Res Treat. 2016;155(3):423\u201330.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"1661_CR24","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa044383","volume":"353","author":"LC Hartmann","year":"2005","unstructured":"Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, et al. Benign breast disease and the risk of breast cancer. N Engl J Med. 2005;353(3):229\u201337.","journal-title":"N Engl J Med"},{"issue":"1","key":"1661_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10552-009-9435-7","volume":"21","author":"JA Westman","year":"2010","unstructured":"Westman JA, Ferketich AK, Kauffman RM, MacEachern SN, Wilkins JR 3rd, Wilcox PP, et al. Low cancer incidence rates in Ohio Amish. Cancer Causes Control. 2010;21(1):69\u201375.","journal-title":"Cancer Causes Control"},{"issue":"8","key":"1661_CR26","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/cncr.20978","volume":"103","author":"A Fregene","year":"2005","unstructured":"Fregene A, Newman LA. Breast cancer in sub-Saharan Africa: how does it relate to breast cancer in African-American women? Cancer. 2005;103(8):1540\u201350.","journal-title":"Cancer"},{"issue":"9","key":"1661_CR27","doi-asserted-by":"publisher","first-page":"e3065","DOI":"10.1210\/clinem\/dgaa404","volume":"105","author":"HJT Coelingh Bennink","year":"2020","unstructured":"Coelingh Bennink HJT, Egberts JFM, Mol JA, Roes KCB, van Diest PJ. Breast cancer and major deviations of genetic and gender-related structures and function. J Clin Endocrinol Metab. 2020;105(9):e3065\u201374.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1661_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/09513590.2012.705378","volume":"29","author":"N Mendoza","year":"2013","unstructured":"Mendoza N, Motos MA. Androgen insensitivity syndrome. Gynecol Endocrinol. 2013;29(1):1\u20135.","journal-title":"Gynecol Endocrinol"},{"issue":"3","key":"1661_CR29","doi-asserted-by":"publisher","first-page":"217","DOI":"10.14310\/horm.2002.1201","volume":"7","author":"A Galani","year":"2008","unstructured":"Galani A, Kitsiou-Tzeli S, Sofokleous C, Kanavakis E, Kalpini-Mavrou A. Androgen insensitivity syndrome: clinical features and molecular defects. Hormones (Athens). 2008;7(3):217\u201329.","journal-title":"Hormones (Athens)"},{"issue":"4","key":"1661_CR30","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1016\/j.jpag.2014.08.005","volume":"28","author":"HR Hoefgen","year":"2015","unstructured":"Hoefgen HR, Merritt DF. Invasive ductal carcinoma in a 46, XY partial androgen insensitivity syndrome patient on hormone therapy. J Pediatr Adolesc Gynecol. 2015;28(4):e95\u20137.","journal-title":"J Pediatr Adolesc Gynecol"},{"issue":"9","key":"1661_CR31","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1210\/jcem.86.9.7825","volume":"86","author":"AL Boehmer","year":"2001","unstructured":"Boehmer AL, Brinkmann O, Bruggenwirth H, van Assendelft C, Otten BJ, Verleun-Mooijman MC, et al. Genotype versus phenotype in families with androgen insensitivity syndrome. J Clin Endocrinol Metab. 2001;86(9):4151\u201360.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1661_CR32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1080\/09513590802288291","volume":"25","author":"C Sultan","year":"2009","unstructured":"Sultan C, Biason-Lauber A, Philibert P. Mayer\u2013Rokitansky\u2013Kuster\u2013Hauser syndrome: recent clinical and genetic findings. Gynecol Endocrinol. 2009;25(1):8\u201311.","journal-title":"Gynecol Endocrinol"},{"issue":"6","key":"1661_CR33","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s00404-017-4372-2","volume":"295","author":"S Choussein","year":"2017","unstructured":"Choussein S, Nasioudis D, Schizas D, Economopoulos KP. Mullerian dysgenesis: a critical review of the literature. Arch Gynecol Obstet. 2017;295(6):1369\u201381.","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"1661_CR34","first-page":"3","volume":"30","author":"S Ledig","year":"2018","unstructured":"Ledig S, Wieacker P. Clinical and genetic aspects of Mayer\u2013Rokitansky\u2013Kuster\u2013Hauser syndrome. Med Genet. 2018;30(1):3\u201311.","journal-title":"Med Genet"},{"issue":"6","key":"1661_CR35","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1093\/hmg\/ddv621","volume":"25","author":"R Prunskaite-Hyyrylainen","year":"2016","unstructured":"Prunskaite-Hyyrylainen R, Skovorodkin I, Xu Q, Miinalainen I, Shan J, Vainio SJ. Wnt4 coordinates directional cell migration and extension of the Mullerian duct essential for ontogenesis of the female reproductive tract. Hum Mol Genet. 2016;25(6):1059\u201373.","journal-title":"Hum Mol Genet"},{"issue":"6718","key":"1661_CR36","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/17068","volume":"397","author":"S Vainio","year":"1999","unstructured":"Vainio S, Heikkila M, Kispert A, Chin N, McMahon AP. Female development in mammals is regulated by Wnt-4 signalling. Nature. 1999;397(6718):405\u20139.","journal-title":"Nature"},{"issue":"6","key":"1661_CR37","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1101\/gad.14.6.650","volume":"14","author":"C Brisken","year":"2000","unstructured":"Brisken C, Heineman A, Chavarria T, Elenbaas B, Tan J, Dey SK, et al. Essential function of Wnt-4 in mammary gland development downstream of progesterone signaling. Genes Dev. 2000;14(6):650\u20134.","journal-title":"Genes Dev"},{"issue":"23","key":"1661_CR38","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1242\/dev.048983","volume":"137","author":"K Kashimada","year":"2010","unstructured":"Kashimada K, Koopman P. Sry: the master switch in mammalian sex determination. Development. 2010;137(23):3921\u201330.","journal-title":"Development"},{"issue":"5","key":"1661_CR39","first-page":"744","volume":"37","author":"E Kasap","year":"2016","unstructured":"Kasap E, Gene M, Sahin N, Sivrikoz ON. Mayer\u2013Rokitansky\u2013Kuster\u2013Hauser syndrome accompanied by invasive ductal carcinoma: a case report. Eur J Gynaecol Oncol. 2016;37(5):744\u20136.","journal-title":"Eur J Gynaecol Oncol"},{"issue":"1","key":"1661_CR40","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s13023-020-01491-9","volume":"15","author":"MK Herlin","year":"2020","unstructured":"Herlin MK, Petersen MB, Brannstrom M. Mayer\u2013Rokitansky\u2013Kuster\u2013Hauser (MRKH) syndrome: a comprehensive update. Orphanet J Rare Dis. 2020;15(1):214.","journal-title":"Orphanet J Rare Dis"},{"key":"1661_CR41","unstructured":"ACOG Committee Opinion No. 728, January 2018. M\u00fcllerian Agenesis: Diagnosis, Management, and Treatment https:\/\/www.acog.org\/clinical\/clinical-guidance\/committee-opinion\/articles\/2018\/01\/mullerian-agenesis-diagnosis-management-and-treatment (accessed on April 11, 2022)."},{"issue":"10","key":"1661_CR42","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1001\/jama.291.10.1226","volume":"291","author":"KB Michels","year":"2004","unstructured":"Michels KB, Ekbom A. Caloric restriction and incidence of breast cancer. JAMA. 2004;291(10):1226\u201330.","journal-title":"JAMA"},{"issue":"5","key":"1661_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128018","volume":"10","author":"L Mellemkjaer","year":"2015","unstructured":"Mellemkjaer L, Papadopoulos FC, Pukkala E, Ekbom A, Gissler M, Christensen J, et al. Cancer incidence among patients with Anorexia Nervosa from Sweden, Denmark and Finland. PLoS ONE. 2015;10(5): e0128018.","journal-title":"PLoS ONE"},{"issue":"2","key":"1661_CR44","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1158\/1055-9965.EPI-16-0587","volume":"26","author":"KM O'Brien","year":"2017","unstructured":"O\u2019Brien KM, Whelan DR, Sandler DP, Weinberg CR. Eating disorders and breast cancer. Cancer Epidemiol Biomarkers Prev. 2017;26(2):206\u201311.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1661_CR45","unstructured":"DSM-5. Diagnostic and Statistical Manual of Mental Disorders. 2013."},{"issue":"7","key":"1661_CR46","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/ijc.28495","volume":"134","author":"G Karamanis","year":"2014","unstructured":"Karamanis G, Skalkidou A, Tsakonas G, Brandt L, Ekbom A, Ekselius L, et al. Cancer incidence and mortality patterns in women with anorexia nervosa. Int J Cancer. 2014;134(7):1751\u20137.","journal-title":"Int J Cancer"},{"issue":"1","key":"1661_CR47","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/humrep\/deh098","volume":"19","author":"Rotterdam, ESHRE-ASRM-Sponsored PCOS consensus workshop group","year":"2004","unstructured":"Rotterdam, ESHRE-ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41\u20137.","journal-title":"Hum Reprod"},{"key":"1661_CR48","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40738-016-0029-2","volume":"2","author":"HR Harris","year":"2016","unstructured":"Harris HR, Terry KL. Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review. Fertil Res Pract. 2016;2:14.","journal-title":"Fertil Res Pract"},{"issue":"6","key":"1661_CR49","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1056\/NEJMcp0808697","volume":"360","author":"LM Nelson","year":"2009","unstructured":"Nelson LM. Clinical practice. Primary ovarian insufficiency. N Engl J Med. 2009;360(6):606\u201314.","journal-title":"N Engl J Med"},{"issue":"9744","key":"1661_CR50","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/S0140-6736(10)60355-8","volume":"376","author":"M De Vos","year":"2010","unstructured":"De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency. Lancet. 2010;376(9744):911\u201321.","journal-title":"Lancet"},{"key":"1661_CR51","unstructured":"ACOG Committee Opinion No. 698 (reaffirmed 2021). Hormone therapy in primary ovarian insufficiency. https:\/\/www.acog.org\/clinical\/clinical-guidance\/committee-opinion\/articles\/2017\/05\/hormone-therapy-in-primary-ovarian-insufficiency (accessed on April 11, 2022)."},{"issue":"3","key":"1661_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089597","volume":"9","author":"X Wu","year":"2014","unstructured":"Wu X, Cai H, Kallianpur A, Li H, Yang G, Gao J, et al. Impact of premature ovarian failure on mortality and morbidity among Chinese women. PLoS ONE. 2014;9(3): e89597.","journal-title":"PLoS ONE"},{"issue":"4","key":"1661_CR53","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1097\/01.ede.0000165392.35273.d4","volume":"16","author":"ME Ossewaarde","year":"2005","unstructured":"Ossewaarde ME, Bots ML, Verbeek AL, Peeters PH, van der Graaf Y, Grobbee DE, et al. Age at menopause, cause-specific mortality and total life expectancy. Epidemiology. 2005;16(4):556\u201362.","journal-title":"Epidemiology"},{"issue":"3","key":"1661_CR54","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1023\/A:1006277207963","volume":"55","author":"EM Monninkhof","year":"1999","unstructured":"Monninkhof EM, van der Schouw YT, Peeters PH. Early age at menopause and breast cancer: are leaner women more protected? A prospective analysis of the Dutch DOM cohort. Breast Cancer Res Treat. 1999;55(3):285\u201391.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"1661_CR55","first-page":"147","volume":"6","author":"AJ Fenton","year":"2015","unstructured":"Fenton AJ. Premature ovarian insufficiency: pathogenesis and management. J Midlife Health. 2015;6(4):147\u201353.","journal-title":"J Midlife Health"},{"issue":"5","key":"1661_CR56","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1080\/13697137.2020.1804547","volume":"23","author":"N Panay","year":"2020","unstructured":"Panay N, Anderson RA, Nappi RE, Vincent AJ, Vujovic S, Webber L, et al. Premature ovarian insufficiency: an International Menopause Society White Paper. Climacteric. 2020;23(5):426\u201346.","journal-title":"Climacteric"},{"issue":"17","key":"1661_CR57","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1093\/jnci\/91.17.1475","volume":"91","author":"TR Rebbeck","year":"1999","unstructured":"Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 1999;91(17):1475\u20139.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"1661_CR58","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.maturitas.2009.08.003","volume":"65","author":"LT Shuster","year":"2010","unstructured":"Shuster LT, Rhodes DJ, Gostout BS, Grossardt BR, Rocca WA. Premature menopause or early menopause: long-term health consequences. Maturitas. 2010;65(2):161\u20136.","journal-title":"Maturitas"},{"issue":"7","key":"1661_CR59","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1158\/1055-9965.EPI-12-0043","volume":"21","author":"RJ Santen","year":"2012","unstructured":"Santen RJ, Yue W, Heitjan DF. Modeling of the growth kinetics of occult breast tumors: role in interpretation of studies of prevention and menopausal hormone therapy. Cancer Epidemiol Biomarkers Prev. 2012;21(7):1038\u201348.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"9017","key":"1661_CR60","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/S0140-6736(96)90806-5","volume":"347","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"1996","unstructured":"Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347(9017):1713\u201327.","journal-title":"Lancet"},{"issue":"10","key":"1661_CR61","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.4065\/81.10.1290","volume":"81","author":"C Kahlenborn","year":"2006","unstructured":"Kahlenborn C, Modugno F, Potter DM, Severs WB. Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. Mayo Clin Proc. 2006;81(10):1290\u2013302.","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"1661_CR62","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3109\/13625187.2012.715357","volume":"17","author":"H Zhu","year":"2012","unstructured":"Zhu H, Lei X, Feng J, Wang Y. Oral contraceptive use and risk of breast cancer: a meta-analysis of prospective cohort studies. Eur J Contracept Reprod Health Care. 2012;17(6):402\u201314.","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"6","key":"1661_CR63","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.ajog.2021.12.022","volume":"226","author":"NA Burchardt","year":"2022","unstructured":"Burchardt NA, Eliassen AH, Shafrir AL, Rosner B, Tamimi R, Kaaks R, et al. Oral contraceptive use by formulation and breast cancer risk by subtype in the Nurses\u2019 Health Study II: a prospective cohort study. Am J Obstet Gynecol. 2022;226(6):821.","journal-title":"Am J Obstet Gynecol"},{"issue":"23","key":"1661_CR64","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1056\/NEJMoa1700732","volume":"377","author":"LS Morch","year":"2017","unstructured":"Morch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard O. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med. 2017;377(23):2228\u201339.","journal-title":"N Engl J Med"},{"issue":"3","key":"1661_CR65","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"JE Rossouw","year":"2002","unstructured":"Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321\u201333.","journal-title":"JAMA"},{"issue":"6","key":"1661_CR66","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1080\/13697137.2018.1514008","volume":"21","author":"HN Hodis","year":"2018","unstructured":"Hodis HN, Sarrel PM. Menopausal hormone therapy and breast cancer: what is the evidence from randomized trials? Climacteric. 2018;21(6):521\u20138.","journal-title":"Climacteric"},{"issue":"14","key":"1661_CR67","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","volume":"291","author":"GL Anderson","year":"2004","unstructured":"Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women\u2019s Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701\u201312.","journal-title":"JAMA"},{"issue":"10","key":"1661_CR68","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1001\/jama.2017.11217","volume":"318","author":"JE Manson","year":"2017","unstructured":"Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the women\u2019s health initiative randomized trials. JAMA. 2017;318(10):927\u201338.","journal-title":"JAMA"},{"issue":"13","key":"1661_CR69","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1056\/NEJMcp1008161","volume":"364","author":"LJ Gooren","year":"2011","unstructured":"Gooren LJ. Clinical practice. Care of transsexual persons. N Engl J Med. 2011;364(13):1251\u20137.","journal-title":"N Engl J Med"},{"issue":"12","key":"1661_CR70","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1111\/jsm.12319","volume":"10","author":"LJ Gooren","year":"2013","unstructured":"Gooren LJ, van Trotsenburg MA, Giltay EJ, van Diest PJ. Breast cancer development in transsexual subjects receiving cross-sex hormone treatment. J Sex Med. 2013;10(12):3129\u201334.","journal-title":"J Sex Med"},{"issue":"5","key":"1661_CR71","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1111\/jsm.12487","volume":"11","author":"K Wierckx","year":"2014","unstructured":"Wierckx K, Gooren L, T\u2019Sjoen G. Clinical review: breast development in trans women receiving cross-sex hormones. J Sex Med. 2014;11(5):1240\u20137.","journal-title":"J Sex Med"},{"issue":"1","key":"1661_CR72","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s10549-014-3213-2","volume":"149","author":"GR Brown","year":"2015","unstructured":"Brown GR, Jones KT. Incidence of breast cancer in a cohort of 5135 transgender veterans. Breast Cancer Res Treat. 2015;149(1):191\u20138.","journal-title":"Breast Cancer Res Treat"},{"key":"1661_CR73","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l1652","volume":"365","author":"CJM de Blok","year":"2019","unstructured":"de Blok CJM, Wiepjes CM, Nota NM, van Engelen K, Adank MA, Dreijerink KMA, et al. Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. BMJ. 2019;365: l1652.","journal-title":"BMJ"},{"key":"1661_CR74","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.maturitas.2019.08.009","volume":"129","author":"JM Patel","year":"2019","unstructured":"Patel JM, Dolitsky S, Bachman GA, Buckley de Meritens A. Gynecologic cancer screening in the transgender male population and its current challenges. Maturitas. 2019;129:40\u20134.","journal-title":"Maturitas"},{"issue":"Suppl 4","key":"1661_CR75","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/annonc\/mdp116","volume":"20","author":"J Balmana","year":"2009","unstructured":"Balmana J, Diez O, Castiglione M, Group EGW. BRCA in breast cancer: ESMO clinical recommendations. Ann Oncol. 2009;20(Suppl 4):19\u201320.","journal-title":"Ann Oncol"},{"issue":"10","key":"1661_CR76","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.ejso.2018.06.021","volume":"44","author":"JP Stone","year":"2018","unstructured":"Stone JP, Hartley RL, Temple-Oberle C. Breast cancer in transgender patients: a systematic review. Part 2: Female to Male. Eur J Surg Oncol. 2018;44(10):1463\u20138.","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"1661_CR77","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1152\/physrev.00040.2018","volume":"100","author":"NY Fu","year":"2020","unstructured":"Fu NY, Nolan E, Lindeman GJ, Visvader JE. Stem cells and the differentiation hierarchy in mammary gland development. Physiol Rev. 2020;100(2):489\u2013523.","journal-title":"Physiol Rev"},{"issue":"7072","key":"1661_CR78","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nature04372","volume":"439","author":"M Shackleton","year":"2006","unstructured":"Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML, et al. Generation of a functional mammary gland from a single stem cell. Nature. 2006;439(7072):84\u20138.","journal-title":"Nature"},{"issue":"7079","key":"1661_CR79","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/nature04496","volume":"439","author":"J Stingl","year":"2006","unstructured":"Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D, et al. Purification and unique properties of mammary epithelial stem cells. Nature. 2006;439(7079):993\u20137.","journal-title":"Nature"},{"issue":"12","key":"1661_CR80","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a003178","volume":"2","author":"C Brisken","year":"2010","unstructured":"Brisken C, O\u2019Malley B. Hormone action in the mammary gland. Cold Spring Harb Perspect Biol. 2010;2(12): a003178.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"7372","key":"1661_CR81","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nature10573","volume":"479","author":"A Van Keymeulen","year":"2011","unstructured":"Van Keymeulen A, Rocha AS, Ousset M, Beck B, Bouvencourt G, Rock J, et al. Distinct stem cells contribute to mammary gland development and maintenance. Nature. 2011;479(7372):189\u201393.","journal-title":"Nature"},{"issue":"1\u20132","key":"1661_CR82","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.mce.2012.04.010","volume":"361","author":"HN Hilton","year":"2012","unstructured":"Hilton HN, Graham JD, Kantimm S, Santucci N, Cloosterman D, Huschtscha LI, et al. Progesterone and estrogen receptors segregate into different cell subpopulations in the normal human breast. Mol Cell Endocrinol. 2012;361(1\u20132):191\u2013201.","journal-title":"Mol Cell Endocrinol"},{"issue":"4","key":"1661_CR83","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/wdev.35","volume":"1","author":"H Macias","year":"2012","unstructured":"Macias H, Hinck L. Mammary gland development. Wiley Interdiscip Rev Dev Biol. 2012;1(4):533\u201357.","journal-title":"Wiley Interdiscip Rev Dev Biol"},{"issue":"1","key":"1661_CR84","doi-asserted-by":"publisher","first-page":"T81","DOI":"10.1530\/JME-20-0091","volume":"65","author":"C Brisken","year":"2020","unstructured":"Brisken C, Scabia V. 90 Years of progesterone: progesterone receptor signaling in the normal breast and its implications for cancer. J Mol Endocrinol. 2020;65(1):T81\u201394.","journal-title":"J Mol Endocrinol"},{"issue":"7","key":"1661_CR85","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1073\/pnas.0915148107","volume":"107","author":"M Beleut","year":"2010","unstructured":"Beleut M, Rajaram RD, Caikovski M, Ayyanan A, Germano D, Choi Y, et al. Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci USA. 2010;107(7):2989\u201394.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"1661_CR86","doi-asserted-by":"publisher","first-page":"R26","DOI":"10.1186\/bcr3627","volume":"16","author":"I Pardo","year":"2014","unstructured":"Pardo I, Lillemoe HA, Blosser RJ, Choi M, Sauder CA, Doxey DK, et al. Next-generation transcriptome sequencing of the premenopausal breast epithelium using specimens from a normal human breast tissue bank. Breast Cancer Res. 2014;16(2):R26.","journal-title":"Breast Cancer Res"},{"issue":"182","key":"1661_CR87","doi-asserted-by":"publisher","first-page":"182ra55","DOI":"10.1126\/scitranslmed.3005654","volume":"5","author":"T Tanos","year":"2013","unstructured":"Tanos T, Sflomos G, Echeverria PC, Ayyanan A, Gutierrez M, Delaloye JF, et al. Progesterone\/RANKL is a major regulatory axis in the human breast. Sci Transl Med. 2013;5(182):182ra55.","journal-title":"Sci Transl Med."},{"issue":"5","key":"1661_CR88","doi-asserted-by":"publisher","first-page":"641","DOI":"10.15252\/embj.201490434","volume":"34","author":"RD Rajaram","year":"2015","unstructured":"Rajaram RD, Buric D, Caikovski M, Ayyanan A, Rougemont J, Shan J, et al. Progesterone and Wnt4 control mammary stem cells via myoepithelial crosstalk. EMBO J. 2015;34(5):641\u201352.","journal-title":"EMBO J"},{"issue":"7320","key":"1661_CR89","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nature09387","volume":"468","author":"D Schramek","year":"2010","unstructured":"Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature. 2010;468(7320):98\u2013102.","journal-title":"Nature"},{"issue":"7299","key":"1661_CR90","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nature09027","volume":"465","author":"ML Asselin-Labat","year":"2010","unstructured":"Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER, et al. Control of mammary stem cell function by steroid hormone signalling. Nature. 2010;465(7299):798\u2013802.","journal-title":"Nature"},{"issue":"7320","key":"1661_CR91","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nature09495","volume":"468","author":"E Gonzalez-Suarez","year":"2010","unstructured":"Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature. 2010;468(7320):103\u20137.","journal-title":"Nature"},{"issue":"14","key":"1661_CR92","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2018100852","volume":"38","author":"P Tharmapalan","year":"2019","unstructured":"Tharmapalan P, Mahendralingam M, Berman HK, Khokha R. Mammary stem cells and progenitors: targeting the roots of breast cancer for prevention. EMBO J. 2019;38(14): e100852.","journal-title":"EMBO J"},{"issue":"2","key":"1661_CR93","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1210\/endrev\/bnz001","volume":"41","author":"B Trabert","year":"2020","unstructured":"Trabert B, Sherman ME, Kannan N, Stanczyk FZ. Progesterone and breast cancer. Endocr Rev. 2020;41(2):320\u201344.","journal-title":"Endocr Rev"},{"issue":"7793","key":"1661_CR94","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, et al. The repertoire of mutational signatures in human cancer. Nature. 2020;578(7793):94\u2013101.","journal-title":"Nature"},{"issue":"5","key":"1661_CR95","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.cell.2012.04.024","volume":"149","author":"S Nik-Zainal","year":"2012","unstructured":"Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, et al. Mutational processes molding the genomes of 21 breast cancers. Cell. 2012;149(5):979\u201393.","journal-title":"Cell"},{"issue":"5","key":"1661_CR96","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.cell.2012.04.023","volume":"149","author":"S Nik-Zainal","year":"2012","unstructured":"Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW, et al. The life history of 21 breast cancers. Cell. 2012;149(5):994\u20131007.","journal-title":"Cell"},{"issue":"7605","key":"1661_CR97","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature17676","volume":"534","author":"S Nik-Zainal","year":"2016","unstructured":"Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016;534(7605):47\u201354.","journal-title":"Nature"},{"key":"1661_CR98","doi-asserted-by":"publisher","first-page":"11383","DOI":"10.1038\/ncomms11383","volume":"7","author":"S Morganella","year":"2016","unstructured":"Morganella S, Alexandrov LB, Glodzik D, Zou X, Davies H, Staaf J, et al. The topography of mutational processes in breast cancer genomes. Nat Commun. 2016;7:11383.","journal-title":"Nat Commun"},{"issue":"11","key":"1661_CR99","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.tig.2021.07.003","volume":"37","author":"K Cervantes-Gracia","year":"2021","unstructured":"Cervantes-Gracia K, Gramalla-Schmitz A, Weischedel J, Chahwan R. APOBECs orchestrate genomic and epigenomic editing across health and disease. Trends Genet. 2021;37(11):1028\u201343.","journal-title":"Trends Genet"},{"issue":"7437","key":"1661_CR100","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/nature11881","volume":"494","author":"MB Burns","year":"2013","unstructured":"Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B, et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature. 2013;494(7437):366\u201370.","journal-title":"Nature"},{"issue":"10","key":"1661_CR101","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1158\/2159-8290.CD-20-0725","volume":"11","author":"S Venkatesan","year":"2021","unstructured":"Venkatesan S, Angelova M, Puttick C, Zhai H, Caswell DR, Lu WT, et al. Induction of APOBEC3 exacerbates DNA replication stress and chromosomal instability in early breast and lung cancer evolution. Cancer Discov. 2021;11(10):2456\u201373.","journal-title":"Cancer Discov"},{"issue":"3","key":"1661_CR102","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1093\/nar\/gky1316","volume":"47","author":"JCF Ng","year":"2019","unstructured":"Ng JCF, Quist J, Grigoriadis A, Malim MH, Fraternali F. Pan-cancer transcriptomic analysis dissects immune and proliferative functions of APOBEC3 cytidine deaminases. Nucleic Acids Res. 2019;47(3):1178\u201394.","journal-title":"Nucleic Acids Res"},{"issue":"7793","key":"1661_CR103","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41586-019-1907-7","volume":"578","author":"M Gerstung","year":"2020","unstructured":"Gerstung M, Jolly C, Leshchiner I, Dentro SC, Gonzalez S, Rosebrock D, et al. The evolutionary history of 2658 cancers. Nature. 2020;578(7793):122\u20138.","journal-title":"Nature"},{"issue":"7794","key":"1661_CR104","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41586-020-1961-1","volume":"578","author":"K Yoshida","year":"2020","unstructured":"Yoshida K, Gowers KHC, Lee-Six H, Chandrasekharan DP, Coorens T, Maughan EF, et al. Tobacco smoking and somatic mutations in human bronchial epithelium. Nature. 2020;578(7794):266\u201372.","journal-title":"Nature"},{"issue":"7779","key":"1661_CR105","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41586-019-1672-7","volume":"574","author":"H Lee-Six","year":"2019","unstructured":"Lee-Six H, Olafsson S, Ellis P, Osborne RJ, Sanders MA, Moore L, et al. The landscape of somatic mutation in normal colorectal epithelial cells. Nature. 2019;574(7779):532\u20137.","journal-title":"Nature"},{"issue":"7739","key":"1661_CR106","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41586-018-0811-x","volume":"565","author":"A Yokoyama","year":"2019","unstructured":"Yokoyama A, Kakiuchi N, Yoshizato T, Nannya Y, Suzuki H, Takeuchi Y, et al. Age-related remodelling of oesophageal epithelia by mutated cancer drivers. Nature. 2019;565(7739):312\u20137.","journal-title":"Nature"},{"issue":"6512","key":"1661_CR107","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1126\/science.aba8347","volume":"370","author":"ARJ Lawson","year":"2020","unstructured":"Lawson ARJ, Abascal F, Coorens THH, Hooks Y, O\u2019Neill L, Latimer C, et al. Extensive heterogeneity in somatic mutation and selection in the human bladder. Science. 2020;370(6512):75\u201382.","journal-title":"Science"},{"issue":"1","key":"1661_CR108","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0046-8177(77)80066-X","volume":"8","author":"JS Meyer","year":"1977","unstructured":"Meyer JS. Cell proliferation in normal human breast ducts, fibroadenomas, and other ductal hyperplasias measured by nuclear labeling with tritiated thymidine. Effects of menstrual phase, age, and oral contraceptive hormones. Hum Pathol. 1977;8(1):67\u201381.","journal-title":"Hum Pathol"},{"issue":"2","key":"1661_CR109","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/bjc.1988.185","volume":"58","author":"CS Potten","year":"1988","unstructured":"Potten CS, Watson RJ, Williams GT, Tickle S, Roberts SA, Harris M, et al. The effect of age and menstrual cycle upon proliferative activity of the normal human breast. Br J Cancer. 1988;58(2):163\u201370.","journal-title":"Br J Cancer"},{"issue":"2","key":"1661_CR110","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41568-019-0222-9","volume":"20","author":"M Fane","year":"2020","unstructured":"Fane M, Weeraratna AT. How the ageing microenvironment influences tumour progression. Nat Rev Cancer. 2020;20(2):89\u2013106.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"1661_CR111","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.bjps.2014.10.001","volume":"67","author":"LA Jansen","year":"2014","unstructured":"Jansen LA, Backstein RM, Brown MH. Breast size and breast cancer: a systematic review. J Plast Reconstr Aesthet Surg. 2014;67(12):1615\u201323.","journal-title":"J Plast Reconstr Aesthet Surg"},{"issue":"5","key":"1661_CR112","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/00008469-199610000-00005","volume":"5","author":"A Tavani","year":"1996","unstructured":"Tavani A, Pregnolato A, La Vecchia C, Negri E, Favero A, Franceschi S. Breast size and breast cancer risk. Eur J Cancer Prev. 1996;5(5):337\u201342.","journal-title":"Eur J Cancer Prev"},{"issue":"5","key":"1661_CR113","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1530\/REP-16-0408","volume":"153","author":"PG Oppelt","year":"2017","unstructured":"Oppelt PG, Muller A, Stephan L, Dittrich R, Lermann J, Buttner C, et al. Hyperandrogenemia and high prolactin in congenital utero-vaginal aplasia patients. Reproduction. 2017;153(5):555\u201363.","journal-title":"Reproduction"},{"issue":"3","key":"1661_CR114","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1054\/bjoc.1999.0987","volume":"82","author":"G Wyshak","year":"2000","unstructured":"Wyshak G, Frisch RE. Breast cancer among former college athletes compared to non-athletes: a 15-year follow-up. Br J Cancer. 2000;82(3):726\u201330.","journal-title":"Br J Cancer"},{"issue":"9","key":"1661_CR115","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S2352-4642(18)30145-7","volume":"2","author":"KE Ackerman","year":"2018","unstructured":"Ackerman KE, Misra M. Amenorrhoea in adolescent female athletes. Lancet Child Adolesc Health. 2018;2(9):677\u201388.","journal-title":"Lancet Child Adolesc Health"},{"issue":"12","key":"1661_CR116","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1158\/1055-9965.EPI-17-0900","volume":"27","author":"CE Matthews","year":"2018","unstructured":"Matthews CE, Sampson JN, Brenner DR, Moore SC, Courneya KS, Ziegler RG, et al. Effects of exercise and cardiorespiratory fitness on estrogen metabolism in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2018;27(12):1480\u20132.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"1661_CR117","first-page":"47","volume":"61","author":"FM Anedda","year":"2004","unstructured":"Anedda FM, Velati A, Lello S, Orru M, Paoletti AM, Melis GB, et al. Observational study on the efficacy of tibolone in counteracting early carotid atherosclerotic lesions in postmenopausal women. Horm Res. 2004;61(1):47\u201352.","journal-title":"Horm Res"},{"issue":"4","key":"1661_CR118","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1001\/jama.2020.9482","volume":"324","author":"RT Chlebowski","year":"2020","unstructured":"Chlebowski RT, Anderson GL, Aragaki AK, Manson JE, Stefanick ML, Pan K, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women\u2019s health initiative randomized clinical trials. JAMA. 2020;324(4):369\u201380.","journal-title":"JAMA"},{"key":"1661_CR119","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0083-6729(08)60522-1","volume":"35","author":"M Levitz","year":"1977","unstructured":"Levitz M, Young BK. Estrogens in pregnancy. Vitam Horm. 1977;35:109\u201347.","journal-title":"Vitam Horm"},{"issue":"8","key":"1661_CR120","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/0002-9378(72)90185-8","volume":"112","author":"D Tulchinsky","year":"1972","unstructured":"Tulchinsky D, Hobel CJ, Yeager E, Marshall JR. Plasma estrone, estradiol, estriol, progesterone, and 17-hydroxyprogesterone in human pregnancy. I. Normal pregnancy. Am J Obstet Gynecol. 1972;112(8):1095\u2013100.","journal-title":"Am J Obstet Gynecol"},{"key":"1661_CR121","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1210\/jcem-40-4-560","volume":"40","author":"D Tulchinsky","year":"1975","unstructured":"Tulchinsky D, Frigoletto FD, Ryan KJ, Fishman J. Plasma estetrol as an index of fetal well-being. J Clin Endocrinol Metab. 1975;40:560\u20137.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-023-01661-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-023-01661-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-023-01661-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T10:10:07Z","timestamp":1685441407000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-023-01661-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,30]]},"references-count":121,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1661"],"URL":"https:\/\/doi.org\/10.1186\/s13058-023-01661-0","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,30]]},"assertion":[{"value":"1 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HJTCB is President, IJS is Director R&D and JK is Chief Medical Officer of Pantarhei Oncology (subsidiary of Pantarhei Bioscience), the company developing the fetal estrogen estetrol for the treatment of advanced breast and prostate cancer, but this is outside the scope of the present review. The other authors have nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}